Clinical trialNCT05190471RecruitingPhase 1Interventional

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

SponsorBio-Path Holdings, Inc.Enrollment48Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gail J Roboz, MD
Weill Cornell Medical College - New York-Presbyterian Hospital
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Scripps Green Hospital
La Jolla, California, United States
David Hermel, MD
Recruiting
Ucla Medical Center
Los Angeles, California, United States
Gary Schiller, MD
Recruiting
Weill Cornell Medical College - Newyork-Presbyterian Hospital
New York, New York, United States
Gail J Roboz, MD →
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Maro Ohanian, D.O.
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BP1002; Liposomal Bcl-2 Antisense OligodeoxynucleotideDecitabine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Aug 2022
Primary completion: 31 Mar 2027
Completion: 30 Sept 2027
Last update posted: 10 Mar 2025
Registered enrollment: 48
Registry id: NCT05190471

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.